P. Thorpe

P Peschke, R. Mason, P. Peschke, 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines

Pojen P. Chen, H. Liao, J. Kappes, 2010, The Journal of experimental medicine.

COADMINISTRATION OF LOW‐DOSE LIPOPOLYSACCHARIDE AND SOLUBLE TISSUE FACTOR INDUCES THROMBOSIS AFTER RADIOSURGERY IN AN ANIMAL ARTERIOVENOUS MALFORMATION MODEL

P. Thorpe, M. Stoodley, J. Tu, 2007, Neurosurgery.

Retargeting Adenoviral Vectors to Improve Gene Transfer into Tumors

R. Gerard, P. Thorpe, Richard T. Hogg, 2010, Cancer Gene Therapy.

The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.

G. Janossy, V. Ghetie, P. Thorpe, 1989, Cellular immunology.

Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

J. Minna, R. Brekken, J. Waltenberger, 2000, Cancer research.

Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2

Wei Zhang, L. Ramdas, W. Hittelman, 2011, BMC Cancer.

Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.

J. Minna, E. Castro-Rivera, S. Ran, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Immunotoxins containing ricin or its A chain.

E. Vitetta, P. Thorpe, 1991, Seminars in cell biology.

The angiogenic pathway ‘vascular endothelial growth factor/flk‐1(KDR)‐receptor’ in rheumatoid arthritis and osteoarthritis

A. Harris, K. Gatter, A. Giatromanolaki, 2001, The Journal of pathology.

Strategies for labeling proteins with PARACEST agents.

A. Sherry, M. Woods, Andrei Marconescu, 2011, Bioorganic & medicinal chemistry.

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors

N. Ibrahim, D. Gerber, A. Stopeck, 2011, Clinical Cancer Research.

The use of anti-ricin antibodies to protect mice intoxicated with ricin.

B. Foxwell, P. Thorpe, S. Detre, 1985, Toxicology.

Immunotoxins: magic bullets or misguided missiles?

J. Uhr, E. Vitetta, P. Thorpe, 1993, Trends in pharmacological sciences.

Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.

D. Gerber, P. Thorpe, P. DeRose, 2011, Immunotherapy.

Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium1

Xianming, R. Brekken, Huang, 2006 .

Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer.

A. Harris, V. Georgoulias, K. Gatter, 2000, Cancer research.

Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.

F. Burrows, P. Thorpe, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Antibody-directed targeting of the vasculature of solid tumors

F. Burrows, P. Thorpe, 2004, Breast Cancer Research and Treatment.

Vascular targeting--a new approach to the therapy of solid tumors.

F. Burrows, P. Thorpe, 1994, Pharmacology & therapeutics.

Targeting the vasculature of solid tumors

P. Thorpe, F. Burrows, 1993 .

Vascular endothelial growth factor and vascular targeting of solid tumors.

R. Brekken, P. Thorpe, 2001, Anticancer research.

Tumor infarction by targeting tissue factor to tumor vasculature.

S. Ran, P. Thorpe, 2000, Cancer journal.

Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.

D. Blakey, P. Knowles, P. Thorpe, 1987, Cancer research.

Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B.

P. Knowles, P. Thorpe, 1987, Analytical biochemistry.

Cocktails of ricin a‐chain immunotoxins against different antigens on hodgkin and sternberg‐reed cells have superior anti‐tumor effects against H‐RS cells in vitro and solid Hodgkin tumors in mice

V. Diehl, H. Bohlen, P. Thorpe, 1995, International Journal of Cancer.

Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution.

F. Stirpe, B. Foxwell, G. Wilson, 1985, European journal of biochemistry.

The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.

J. Uhr, P. Knowles, E. Vitetta, 1991, Journal of immunological methods.

Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin

E. Rieber, P. Thorpe, A. Cumber, 2005, Cancer Immunology, Immunotherapy.

Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.

V. Diehl, S. Pileri, P. Thorpe, 1994, Leukemia & lymphoma.

Cytotoxicity of a recombinant ricin‐A‐chain fusion protein containing a proteolytically‐cleavable spacer sequence

L. Roberts, J. Lord, E. Vitetta, 1990, FEBS letters.

Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.

V. Diehl, M. Pfreundschuh, P. Tazzari, 1990, Cancer research.

An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.

J. Uhr, E. Vitetta, P. Thorpe, 1988, Cancer research.

Evaluation of four CD22 antibodies as ricin a chain‐containing immunotoxins for the in vivo therapy of human B‐cell leukemias and lymphomas

J. Uhr, G. Janossy, P. Knowles, 1988, International journal of cancer.

Purification of ricin A1, A2, and B chains and characterization of their toxicity.

J. Uhr, D. Blakey, P. Knowles, 1986, The Journal of biological chemistry.

The removal of carbohydrates from ricin with endoglycosidases H, F and D and α-mannosidase

B. Foxwell, P. Thorpe, T. Donovan, 1985 .

Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.

R. J. Price, D. Blakey, P. Thorpe, 1988, Biochimica et biophysica acta.

Immunotoxins constructed with anti‐CD25 monoclonal antibodies and deglycosylated ricin a‐chain have potent anti‐tumour effects against human hodgkin cells in vitro and solid hodgkin tumours in mice

V. Diehl, G. Martin, P. Thorpe, 1991, International journal of cancer.

Anti‐tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate‐specific membrane antigen

P. Thorpe, Xianming Huang, M. Bennett, 2004, The Prostate.

An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.

F. Stirpe, B. Foxwell, P. Thorpe, 1985, Journal of the National Cancer Institute.

Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro.

F. Burrows, S. Poole, J. Marshall, 1991, Cancer research.

Granulocyte-Colony Stimulating Factor Receptor, Tissue Factor, and VEGF-R Bound VEGF in Human Breast Cancer In Loco.

M. Wojtukiewicz, E. Sierko, P. Thorpe, 2016, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

Prevention of ischemic brain injury by treatment with the membrane penetrating apoptosis inhibitor, TAT-BH4

P. Nicotera, S. Donnini, M. Ziche, 2009, Cell cycle.

Exogenous BH4/Bcl-2 Peptide Reverts Coronary Endothelial Cell Apoptosis Induced by Oxidative Stress

S. Donnini, M. Ziche, P. Thorpe, 2004, Journal of Vascular Research.

Antitumor Effects of Six Ricin A-Chain Immunotoxins of Potential Use in the Treatment of Hodgkin’S Disease

P. Thorpe, A. Engert, 1990 .

Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P.

P. Parker, B. Foxwell, W. Jeffery, 1988, British Journal of Cancer.

Coexpression of MUC 1 Glycoprotein with Multiple Angiogenic Factors in Non-Small Cell Lung Cancer Suggests Coactivation of Angiogenic and Migration Pathways 1

A. Harris, K. Gatter, A. Giatromanolaki, 2000 .

The first international conference on vascular targeting: meeting overview.

D. Blakey, D. Chaplin, P. Thorpe, 2003, Cancer research.

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors

C. Besch-Williford, P. Thorpe, Yayun Liang, 2010, Breast Cancer Research and Treatment.

The First International Conference on Vascular Targeting : Meeting Overview 1

D. Blakey, D. Chaplin, P. Thorpe, 2003 .

TARGETING THE VASCULATURE OF SOLID TUMORS

P. Thorpe, F. Burrows, 1993 .

Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation

Yi Yin, P. Thorpe, Xianming Huang, 2013, Cancer Immunology Research.

Preparation of antibody-toxin conjugates.

B. Foxwell, P. Thorpe, W. Ross, 1985, Methods in enzymology.

A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.

Y. Watanabe, F. Burrows, P. Thorpe, 1992, Cancer research.

Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.

Jon A. Anderson, D. Mathews, D. Gerber, 2015, American journal of nuclear medicine and molecular imaging.

Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine.

P. Thorpe, Xianming Huang, D. Ye, 2011, Vaccine.

Immunotoxins: magic bullets or misguided missiles?

J. Uhr, E. Vitetta, P. Thorpe, 1993, Immunology today.

Antibody-Toxin Conjugates as Potential Therapeutic Agents

D. C. Edwards, P. Thorpe, A. Davies, 1982 .

[16] Preparation of antibody—toxin conjugates

B. Foxwell, P. Thorpe, W. Ross, 1985 .

Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(ab')2 fragment.

D. C. Edwards, P. Thorpe, W. Ross, 1980, European journal of biochemistry.

Role of the B-Chain in the Cytotoxic Action of Antibody-Ricin and Antibody-Abrin Conjugates

P. Thorpe, D. Mcintosh, 1984 .

Oxygenation in a human tumor xenograft: manipulation through respiratory challenge and antibody-directed infarction.

R. Mason, S. Ran, A. Constantinescu, 2003, Advances in experimental medicine and biology.

Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer.

W. Kisiel, R. Brekken, M. Wojtukiewicz, 2011, Anticancer research.

A novel "salting-out" procedure for the isolation of tumor-derived exosomes.

A. Schroit, P. Thorpe, Zachary Brownlee, 2014, Journal of immunological methods.

Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.

P. D. de Groot, C. Mineo, I. Yuhanna, 2011, The Journal of clinical investigation.

In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11

D. Delia, G. Gasparini, P. Thorpe, 1997, Anti-cancer drugs.

The angiogenic “vascular endothelial growth factor/flk‐1(KDR) receptor” pathway in patients with endometrial carcinoma

A. Harris, K. Gatter, A. Giatromanolaki, 2001, Cancer.

Characterization of the cell‐surface procoagulant activity of T‐lymphoblastoid cell lines

A. Goodall, S. Ran, P. Thorpe, 2004, Journal of thrombosis and haemostasis : JTH.

The Potential of Membrane-Acting Toxins for Targeted Cancer Therapy

F. Drobniewski, P. Thorpe, P. Wallace, 1988 .

The preparation of deglycosylated ricin by recombination of glycosidase-treated A- and B-chains: effects of deglycosylation on toxicity and in vivo distribution.

D. Blakey, B. Foxwell, P. Thorpe, 1987, Biochimica et biophysica acta.

The removal of carbohydrates from ricin with endoglycosidases H, F and D and alpha-mannosidase.

B. Foxwell, P. Thorpe, T. Donovan, 1985, Biochimica et biophysica acta.

Antibody toxin conjugates: a perspective.

D. Blakey, P. Thorpe, P. Wallace, 1988, Progress in allergy.

Vascular endothelial growth factor as a marker of tumor endothelium.

R. Brekken, P. Thorpe, Xianming Huang, 1998, Cancer research.

Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines.

W. Wels, B. Ober, P. Thorpe, 2001, BioTechniques.

Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.

L. Barbieri, F. Stirpe, P. Thorpe, 1988, British Journal of Cancer.

Anti‐tumor and anti‐angiogenic effects in mice of heparin conjugated to angiostatic steroids

Y. Yang, P. Thorpe, Yong-ching Yang, 1995, International journal of cancer.

Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells*

P. D. de Groot, A. Schroit, P. Thorpe, 2006, Journal of Biological Chemistry.

Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins.

P. Thorpe, A. Engert, A. Brown, 1991, Leukemia research.

Hepatotoxicity of immunotoxins made with saporin, a ribosome-inactivating protein fromSaponaria officinalis

L. Barbieri, F. Stirpe, M. Derenzini, 1987, Virchows Archiv. B, Cell pathology including molecular pathology.

Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.

V. Diehl, M. Pfreundschuh, G. Martin, 1990, Cancer research.

Organ‐specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene‐targeting of the PI3K regulatory isoforms p85α, p55α, and p50α

L. Cantley, K. Alitalo, D. Fruman, 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

Expression of ricin A chain in Escherichia coli

L. Roberts, J. Lord, P. Thorpe, 1987, FEBS letters.

Modification of the carbohydrate in ricin with metaperiodate and cyanoborohydride mixtures: effect on binding, uptake and toxicity to parenchymal and non-parenchymal cells of rat liver.

R. J. Price, P. Thorpe, D. Skilleter, 1985, Biochimica et biophysica acta.

Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model

F. Burrows, P. Thorpe, J. Overholser, 2007, Cell Biophysics.

Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti‐T cell immunotoxins

G. Janossy, P. Thorpe, A. Cumber, 1987, British journal of haematology.

Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid activities inhibit the proliferation of vascular endothelial cells.

Y. Yang, P. Thorpe, E. Derbyshire, 1996, Biochimica et biophysica acta.

Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice.

P. Knowles, P. Thorpe, Yuh Cheng Yang, 1993, Cancer research.

New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

D. Blakey, P. Knowles, P. Thorpe, 1987, Cancer research.

A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice.

P. Thorpe, Xianming Huang, M. Bennett, 2005, Cancer research.

Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin.

D. C. Edwards, F. Stirpe, P. Thorpe, 1981, European journal of biochemistry.

AN IMMUNOTOXIN OF RICIN A CHAIN CONJUGATED TO THYROGLOBULIN SELECTIVELY SUPPRESSES THE ANTI-THYROGLOBULIN AUTOANTIBODY RESPONSE

A. Weetman, P. Thorpe, R. Hall, 1983, The Lancet.

Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium.

J. Stafford, P. Thorpe, 2011, Neoplasia.

Microplate culture of mouse lymph node cells. I. Quantitation of responses to allogeneic lymphocytes endotoxin and phytomitogens.

P. Thorpe, S. Knight, 1974, Journal of immunological methods.

Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver.

D. Blakey, P. Thorpe, 1988, Cancer treatment and research.

Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis

R. Brekken, C. Mineo, P. Shaul, 2016, PloS one.

Enzymic removal of two oligosaccharide chains from ricin B‐chain

P. Thorpe, E. Wawrzynczak, 1986, FEBS letters.

Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites.

W. Cavenee, M. Nagane, S. Cheng, 2001, Cancer research.

Anatomic Sites Activities in Promoting Tumor Angiogenesis at Different Vascular Endothelial Growth Factor Isoforms Display Distinct Updated

W. Cavenee, M. Nagane, H. Huang, 2001 .

Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites.

W. Cavenee, M. Nagane, H. Huang, 2001, Cancer research.

Effect of chemical deglycosylation on the in vivo fate of ricin A-chain.

D. Blakey, P. Thorpe, 1986, Cancer drug delivery.

Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing neoplastic B cells in vitro.

E. Vitetta, P. Thorpe, 1985, Cancer drug delivery.

Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins.

P. Thorpe, E. Wawrzynczak, 1988, Cancer treatment and research.

The effect of abrin, anti-lymphocyte globulin and their conjugates on the immune response of mice to sheep red blood cells

D. C. Edwards, P. Thorpe, W. Ross, 1981, Experientia.

Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice.

Dawen Zhao, Heling Zhou, P. Thorpe, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.

D. Blakey, P. Knowles, P. Thorpe, 1987, Journal of the National Cancer Institute.

The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

C. Dinney, M. Rosenblum, P. Sweeney, 2005, Neoplasia.

Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer

D. Mukhopadhyay, R. Brekken, Jinping Li, 2004, Clinical Cancer Research.

Near-infrared Optical Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model.

J. Stafford, Dawen Zhao, Heling Zhou, 2011, Translational oncology.

Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy.

S. Ran, P. Thorpe, 2002, International journal of radiation oncology, biology, physics.

Increased exposure of anionic phospholipids on the surface of tumor blood vessels.

S. Ran, P. Thorpe, A. Downes, 2002, Cancer research.

An Orthotopic Lung Tumor Model for Image-Guided Microirradiation in Rats

Timothy D Solberg, Robert Timmerman, Debabrata Saha, 2010, Radiation research.

Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids

P. Thorpe, T. Luster, Jin He, 2007, Clinical Cancer Research.

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

Grietje Molema, Philip E. Thorpe, Xianming Huang, 1997, Science.

Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin

F. Stirpe, M. Glennie, P. Thorpe, 1987, The Journal of experimental medicine.

Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium 1

R. Brekken, P. Thorpe, Xianming Huang, 2006 .

Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas

A. Harris, K. Gatter, A. Giatromanolaki, 2004, Clinical & Experimental Metastasis.

Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2 (FLK-1, KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors

P E Thorpe, E. Manseau, H. Dvorak, 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells.

M. Rosenblum, Yuying Liu, P. Thorpe, 2003, Molecular cancer therapeutics.

A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model

Wei Zhang, S. Ran, P. Thorpe, 2004, Angiogenesis.

Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.

S. Ran, P. Thorpe, Xianming Huang, 2003, Neoplasia.

The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.

S. Ran, M. Rosenblum, P. Thorpe, 2005, Neoplasia.

An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A

M. Greaves, P. Thorpe, W. Ross, 1984 .

An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A.

M. Greaves, P. Thorpe, W. Ross, 1984, Blood.

Selective killing of malignant cells in a leukaemic rat bone marrow using an antibody–ricin conjugate

D. Mason, P. Thorpe, W. Ross, 1982, Nature.

In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A.

T. Lister, M. Horton, P. Thorpe, 1987, Haematology and blood transfusion.

Elimination of leukaemic cells from rodent bone marrow in vitro with antibody-ricin conjugates: Implications for autologous marrow transplantation in man

D. Mason, P. Thorpe, W. Ross, 1982 .

Anti-tumor Effects of Monoclonal Antibody-ricin Conjugates In Vitro and In Vivo

D. Blakey, P. Thorpe, 1988 .

Optimal conditions for the preservation of mouse lymph node cells in liquid nitrogen using cooling rate techniques.

J. Farrant, P. Thorpe, S. Knight, 1976, Cryobiology.

Targeting Inside-Out Phosphatidylserine as a Therapeutic Strategy For Viral Diseases

P. Thorpe, M. Soares, S. King, 2008, Nature Medicine.

Immunotoxins.

D. Blakey, P. Thorpe, 1986, BioEssays : news and reviews in molecular, cellular and developmental biology.

Antibody-Toxin Conjugates as Anti-Cancer Agents

P. Thorpe, 1984 .

Monoclonal antibody therapy: "model" experiments with toxin-conjugated antibodies in mice and rats.

D. Mason, P. Thorpe, W. Ross, 1983, Haematology and blood transfusion.

Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.

A. Gazdar, P. Tazzari, F. Burrows, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice

S. Ran, P. Thorpe, Xianming Huang, 2005, Clinical Cancer Research.

Combination of a monoclonal anti‐phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice

R. Brekken, P. Thorpe, A. Beck, 2006, International journal of cancer.

Antibody Targeting of Tumor Vasculature

P. Thorpe, D. West, J. Wilson, 2002 .

Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma

Jin He, Yi Yin, P. Thorpe, 2009, Clinical Cancer Research.

Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.

M. Rosenblum, C. Sikes, N. Navone, 2006, Cancer research.

Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies

D. Hicklin, R. Kerbel, A. Davidoff, 2004, Cancer Research.

Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.

R. J. Price, D. Newell, D. Blakey, 1988, Cancer research.

Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.

S. Ran, P. Thorpe, B. Gao, 1998, Cancer research.

Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

D. Newell, D. Blakey, P. Knowles, 1988, Cancer research.

Targeting anionic phospholipids on tumor blood vessels and tumor cells.

P. Thorpe, 2010, Thrombosis research.

Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.

V. Diehl, J. Wolf, H. Bohlen, 1994, Blood.

A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.

D. Hicklin, R. Kerbel, S. Man, 2004, Molecular cancer research : MCR.

/ rGel 121 by the Vascular Targeting Agent VEGF Inhibition of Prostate Tumor Growth and Bone Remodeling

M. Rosenblum, C. Sikes, N. Navone, 2006 .

Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.

K. Gatter, A. Giatromanolaki, M. Koukourakis, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Vasculature Antibody-directed Targeting of Tissue Factor to Tumor Infarction of Solid Hodgkin ' s Tumors in Mice by Updated Version

P. Thorpe, B. Gao, N. Rote, 2006 .

Ligand-Directed Destruction of Tumor Vasculature

S. Ran, M. Rosenblum, P. Thorpe, 2002 .

A new method for radiochemical separation of arsenic from irradiated germanium oxide.

R. Mason, N. Slavine, F. Rösch, 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine

Jin He, Vikram D Kodibagkar, Alex Hermanne, 2008, Clinical Cancer Research.

A new method for the labelling of proteins with radioactive arsenic isotopes

Ralph P. Mason, A. Hermanne, Philip E. Thorpe, 2006 .

Quantitative assessment of tumor oxygen dynamics: Molecular imaging for prognostic radiology

R. Mason, S. Ran, P. Thorpe, 2002, Journal of cellular biochemistry. Supplement.

A simple and rapid method for purifying the extracellular domain of human tissue factor.

P. Thorpe, S. Li, B. Gao, 1998, Thrombosis research.

The Development of Ricin A-Chain Immunotoxins for Clinical Trials in Patients with Hodgkin’s Disease

P. Thorpe, A. Engert, 1992 .

Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins.

D. Blakey, P. Thorpe, 1988, Scandinavian journal of rheumatology. Supplement.

Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets Phosphatidylserine

J. Stafford, Xiankai Sun, P. Thorpe, 2013, PloS one.

Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin.

D. C. Edwards, P. Thorpe, W. Ross, 1981, Clinical and experimental immunology.

IBC’s 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society

Jamie K. Scott, J. Reichert, R. Begent, 2012, mAbs.

Phosphatidylserine externalization and membrane blebbing are involved in the nonclassical export of FGF1

Courtney M. Mazur, F. Tarantini, P. Sims, 2012, Journal of cellular biochemistry.

Neuronotoxic effects of monoclonal anti-Thy 1 antibody (OX7) coupled to the ribosome inactivating protein, saporin, as studied by suicide transport experiments in the rat

F. Stirpe, R. Wiley, P. Thorpe, 1989, Brain Research.

VEGF-VEGF receptor complexes as markers of tumor vascular endothelium.

R. Brekken, P. Thorpe, Philip E. Thorpe, 2001, Journal of controlled release : official journal of the Controlled Release Society.

of Tumor Blood Vessels Increased Exposure of Anionic Phospholipids on the Surface Updated

S. Ran, P. Thorpe, A. Downes, 2002 .

Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance.

P E Thorpe, R. Brekken, P. Thorpe, 1998, Biochemical and biophysical research communications.

Phosphatidylserine-targeted molecular imaging of tumor vasculature by magnetic resonance imaging.

R. Mason, Jinming Gao, Gang Huang, 2014, Journal of biomedical nanotechnology.

Semaphorin 3 B ( SEMA 3 B ) induces apoptosis in lung and breast cancer , whereas VEGF 165 antagonizes this effect

J. Minna, E. Castro-Rivera, S. Ran, 2004 .

Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel.

M. Rosenblum, Xiaoyuan Chen, G. Niu, 2012, Biochemical pharmacology.

Circular dichroism of isolated ricin A- and B-chains.

A. Drake, P. Thorpe, E. Wawrzynczak, 1988, Biophysical chemistry.

Identification of a tyrosine residue in the saccharide binding site of ricin B‐chain using N‐[14C]acetylimidazole

A. Falasca, W. Jeffery, P. Thorpe, 1987 .

Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin.

A. Drake, E. Vitetta, P. Thorpe, 1988, Biochimica et biophysica acta.

Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis

R. Brekken, C. Mineo, P. Shaul, 2016, PloS one.

Immunotoxins: magic bullets or misguided missiles?

J. Uhr, E. Vitetta, P. Thorpe, 1993, Trends in pharmacological sciences.

Tumour imaging and drug targeting.

K. Sikora, H. Smedley, P. Thorpe, 1984, British medical bulletin.

Protective Effect of Anti-Phosphatidylserine Antibody in a Guinea Pig Model of Advanced Hemorrhagic Arenavirus Infection

P. Thorpe, John M. Thomas, 2017, The open microbiology journal.

Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine

P. Antich, R. Mason, N. Slavine, 2008, Clinical Cancer Research.

Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.

J. Minna, R. Brekken, J. Waltenberger, 2000, Cancer research.

Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.

J. Uhr, G. Janossy, P. Knowles, 1988, Cancer research.

UTSW Small Animal Positron Emission Imager

G. Arbique, E. Richer, P. Antich, 2006, IEEE Transactions on Nuclear Science.

Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells.

M. Rosenblum, Yuying Liu, P. Thorpe, 2003, Molecular cancer therapeutics.

Phase I immunotoxin trial in patients with B-cell lymphoma.

R. Collins, J. Fay, J. Uhr, 1991, Cancer research.

TAT-BH4 counteracts Abeta toxicity on capillary endothelium.

S. Donnini, M. Ziche, P. Thorpe, 2007, FEBS letters.

Selective killing of contaminating human fibroblasts in epithelial cultures derived from colorectal tumours using an anti Thy-I antibody-ricin conjugate

P. Thorpe, C. Paraskeva, B. Buckle, 2007 .

Targeting toxins — the retiarian approach to chemotherapy

P. Thorpe, D. Edwards, 1981 .